Literature DB >> 11122798

Dose-intensive approaches to ovarian cancer.

N Lambrou1, E L Trimble.   

Abstract

Increasing the total dose or the dose intensity of platinum does not improve survival in women with ovarian cancer. High-dose chemotherapy with hematologic support has not been shown to be more effective than standard-dose chemotherapy. Regional dose intensity, through intraperitoneal chemotherapy, may have a role in the treatment of advanced ovarian cancer. Further studies are needed to identify the optimal combination of agents, in addition to a platinum and a taxane, to be used in primary therapy for ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 11122798     DOI： 10.1007/s11912-999-0010-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  20 in total

1.  High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients.

Authors:  T Shinozuka; T Miyamoto; T Muramatsu; T Hirasawa; M Murakami; T Makino; Y Tanaka
Journal:  Cancer       Date:  1999-04-01       Impact factor: 6.860

2.  Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma.

Authors:  D Coeffic; A Benhammouda; E C Antoine; O Rixe; D Paraiso; G Auclerc; N Renody; E Mularoni; C Soubrane; M Weil; N Mortier; D Khayat
Journal:  Semin Oncol       Date:  1997-02       Impact factor: 4.929

Review 3.  How many more nails to seal the coffin of dose intensity?

Authors:  W P McGuire
Journal:  Ann Oncol       Date:  1997-04       Impact factor: 32.976

Review 4.  First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?

Authors:  A du Bois; J P Neijt; J T Thigpen
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

5.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

Authors:  D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

6.  Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

Authors:  V M Herben; V R Panday; D J Richel; J H Schellens; N van der Vange; H Rosing; F D Beusenberg; S Hearn; E Doyle; J H Beijnen; W W ten Bokkel Huinink
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

7.  Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.

Authors:  M Markman; M F Brady; N M Spirtos; P Hanjani; S C Rubin
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

8.  A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer.

Authors:  R W Naumann; R D Alvarez; G A Omura; E Segars; L C Kilgore; E E Partridge
Journal:  Gynecol Oncol       Date:  1998-12       Impact factor: 5.482

9.  A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.

Authors:  L G Feun; J A Blessing; F J Major; P J DiSaia; R D Alvarez; J S Berek
Journal:  Gynecol Oncol       Date:  1998-12       Impact factor: 5.482

10.  Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.

Authors:  S B Kaye; J Paul; J Cassidy; C R Lewis; I D Duncan; H K Gordon; H C Kitchener; D J Cruickshank; R J Atkinson; M Soukop; E M Rankin; J A Davis; N S Reed; S M Crawford; A MacLean; D Parkin; T K Sarkar; J Kennedy; R P Symonds
Journal:  J Clin Oncol       Date:  1996-07       Impact factor: 44.544
View more
  3 in total

1.  Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study.

Authors:  John H Farley; Chunqiao Tian; G Scott Rose; Carol L Brown; Michael Birrer; John I Risinger; J Tate Thigpen; Gini F Fleming; Holly H Gallion; G Larry Maxwell
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

Review 2.  Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals.

Authors:  F C Muñoz-Casares; S Rufián; M J Rubio; E Lizárraga; C Díaz-Iglesias; E Aranda; R Ciria; J Muntané; P Barrios; J Torres-Melero; S González-Moreno; L González-Bayón; B Camps; P Bretcha; J Farré; G Ortega-Pérez; A Gómez-Portilla
Journal:  Clin Transl Oncol       Date:  2007-10       Impact factor: 3.405

3.  Clinical significance of side population in ovarian cancer cells.

Authors:  Shinji Hosonuma; Yoichi Kobayashi; Satoshi Kojo; Haruka Wada; Ken-ichiro Seino; Kazushige Kiguchi; Bunpei Ishizuka
Journal:  Hum Cell       Date:  2011-01-07       Impact factor: 4.174
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.